Fhrmann ER, Adkins L, Loader CJ, et al
In some embodiments, the formulation or composition comprises between about 0.01% to about 20% by weight of the viscosity modulating agent
The mRNA levels of CCL2 (C-C Motif Chemokine Ligand 2), CCL11 (C-C Motif Chemokine Ligand 11), CSF2 (Colony Stimulating Factor 2), CXCL10 (C-X-C Motif Chemokine Ligand 10), HGF (Hepatocyte Growth Factor), IL1RA (Interleukin 1 Receptor Antagonist), IL6 (Interleukin 6), IL10 (Interleukin 10), IL31 (Interleukin 31), LIF (LIF Interleukin 6 Family Cytokine), and NGF (Nerve Growth Factor) were quantified using specific primers in SYBR Green (Thermo Fisher) or TaqMan (Thermo Fisher) platforms following the manufacturers instructions
Most state Medicaid programs cover it, but rates and rules vary by state
2017 Oct;20(10):89
There is a paucity in the literature of papers addressing molecular mechanisms of new peptide polyagonists and extending these to preclinical and clinical data